Contact Us

Cymbalta
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you stopped taking this drug:

Date you started taking this drug:

Name(s) of all antidepressants taken:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

Was suicide attempted after taking antidepressant(s)?

Did attempted suicide result in death?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Please further describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Cymbalta

cymbalta, antidepressant, paxil, lexapro, suicide, prozac, zoloft, liver disease

Facebook Twitter Stumble AddThis Social Bookmark Button Pin It Email to Friend Print Page
CLICK HERE TO DOWNLOAD OUR CYMBALTA INFORMATION PACKAGE

Cymbalta Side Effects May Lead To Suicide, Birth Defect Lawsuits

Cymbalta Side Effects Include: Suicidal Thoughts, Liver Disease, Birth Defects, Cleft Palate, Heart Valve Damage, SSRI - Personal Injury Lawyers

On December 13, 2006, the FDA announced antidepressants prescribed to young adults are risky. The agency proposed expanding the labels of all antidepressants to include an expanded warning of suicidal thoughts in patients ranging from 18-24 years of age. The newly presented change would expand a warning now on the labels that pertain only to children and adolescents treated with antidepressant drugs. The new label changes would also contain a suggestion that patients of all ages be carefully monitored, particularly when starting antidepressant treatment.

Parker Waichman LLP Cymbalta Side Effects Lawyers Have Years of Experience Handling Defective Drug Lawsuits!

The FDA recently completed a bulk evaluation of 372 studies involving approximately 100,000 patients and 11 antidepressants, including Lexapro, Zoloft, Prozac and Paxil. When the results are analyzed by age, it becomes clear there is an elevated risk for suicidal thoughts and behavior among adults 18 to 25 that approaches that seen in children, the FDA said in documents released before their scheduled December 13, 2006 meeting of its psychopharmacologic drugs advisory committee.

In May 2006, GlaxoSmithKline and the FDA cautioned Paxil may raise the risk of suicidal behavior in young adults too and changed the drugs label to reflect that risk.

On October 17, 2005, Eli Lilly expanded its warning about potential liver-related problems with its depression drug, Cymbalta, and cautioned doctors against prescribing it to patients with chronic liver disease, U.S. health regulators announced. The new label for the drug also contains reports of hepatitis, jaundice and other liver-related problems in patients using Cymbalta.

The FDA has recently issued a new warning about the potential for suicidal thinking in adults taking antidepressants, but the agency specifically singled out Cymbalta (generic: duloxetine) because of a higher than expected rate of suicide attempts in recent studies. Cymbalta is a relatively new antidepressant manufactured by Eli Lilly that has been associated with suicide risk since its clinical trials.

The warning comes after a review of Cymbalta by Eli Lilly; found that 11 of nearly 9,000 women taking it for urinary incontinence tried to commit suicide. The fact that these patients were suffering from urinary incontinence and not depression is significant because the drug companies have long argued that antidepressants are used by depressed people who have a higher likelihood of committing suicide.

Cymbalta has been associated with suicidal behavior since Traci Johnson, a healthy volunteer involved in a trial at Eli Lilly's clinic at Indiana University Medical Center in Indianapolis, killed herself in one of the clinics showers. Johnson, who did not suffer from depression, was taken off the drug and given a placebo four days before she hung herself in one of the clinic's showers on February 7, 2004. Johnson was the fifth patient to commit suicide after taking Cymbalta in clinical trials. After her death one-fifth of the volunteers have quit the Cymbalta trial.

The FDA approved Cymbalta for use as an antidepressant last August 2004 but it is not approved in the United States to treat urinary incontinence. Cymbalta is an important drug for Eli Lilly, as some analysts believe its annual revenues can reach $3 billion by 2009. Cymbalta recorded $94 million in revenues in five months that it was on the market last year and $107 million the first three months of this year. The most recent FDA warning about the risk of suicide associated with antidepressants was different in that it specifically focused on the risk to adults.

Much of the concern over suicide and antidepressants has centered on children who use the drugs. The FDA last fall determined there is a real, but small, increase in risk of suicidal behavior for children and ordered the labels of all antidepressants to say so. The FDA issued a warning that adults, too, may be at increased risk. The agency began reanalyzing hundreds of studies of the drugs to try to determine if that's the case, and told makers to add or strengthen suicide-related warnings on their labels in the meantime. Since then, several new studies have been published in medical journals about a possible connection.

In addition to the aforementioned side effects associated with antidepressants, a new study has linked these drugs to an increased risk of death amongst patients with coronary artery disease. This study, which was conducted at Duke University, analyzed the survival rate of heart disease patients using antidepressants compared with those not using these drugs.

During an average of three years of follow-up, 21.4% of the patients taking antidepressants died compared with 12.5% of those not on antidepressants. After adjusting for demographic factors, cardiac risk factors, scores on the Beck Depression Inventory test, and the presence of other illness, antidepressant use was an independent risk factor for mortality, increasing the risk by 62%.

Researchers do not fully understand why antidepressants increase the risk of mortality in these patients. However their findings are statistically significant and show that these drugs do increase the risk of death in heart disease patients. Current and former heart disease patients should weigh the risks and benefits of antidepressants before using these medications.

Legal Help For Victims Affected By Cymbalta

If you or a loved one took Cymbalta and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified defective drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).

Tags:  
CymbaltaRSS Feed

FDA Says Promotions, Statements by 4 Drug Makers are Misleading

Jan 13, 2010 | Parker Waichman LLP
Four drug makers  have received Food & Drug Administration (FDA) warning letters for misleading promotions and statements about their drugs.  The drugs cited by the letters include the diabetes drug Byetta, which is marketed jointly by Amylin and Eli Lilly, Eli Lilly’s antidepressant Cymbalta,  Bayer’s birth control implant Mirena, and and Cephalon’s Treanda, a lymphoma treatment.The Byetta letter cited statements made by an Eli Lilly representative at the...

Antidepressants Linked to Sudden Cardiac Death in Women

Mar 11, 2009 | Parker Waichman LLP
A new study has concluded that women with no history of cardiac problems but who use antidepressants are at an increased risk for sudden cardiac death (SCD).  HealthDay News reports that the reason for the link remains unknown, according to the researchers whose findings were published in the Journal of the American College of Cardiology."We suspect that their use is a marker for people with worse depression," explained the study’s lead author Dr. William Whang, an...

Lyrica, Cymbalta Fibromyalgia Promotions Questioned

Feb 9, 2009 | Parker Waichman LLP
Two drug makers are spending a fortune to promote medications for a disease that some doctors say may not even exist.  According to the Associated Press, Eli Lilly and Pfizer have donated more than $6 million to nonprofit groups to spread information about fibromyalgia in an effort to boost sales of  Cymbalta and Lyrica.Fibromyalgia, defined as a chronic, widespread pain condition of unknown origin, is a controversial diagnosis.   No biological tests exist to diagnose...

Eli Lilly Withdraws Cymbalta Application

Dec 1, 2008 | Parker Waichman LLP
Eli Lilly and Company has announced that it withdrew an application to market Cymbalta as a treatment for chronic pain.  Reuters is reporting that the application to expand the approved uses of Cymbalta, already approved as an anti-depressant, faced questions from U.S. health regulators over efficacy and dosage recommendations.Lilly said its move to pull the supplemental New Drug Application (NDA) for Cymbalta—known generically as duloxetine HCl—was prompted by  FDA...

Cymbalta Suicide Data Withheld by FDA

Apr 16, 2008 | Parker Waichman LLP
Cymbalta, an antidepressant made by Eli Lilly, has been linked to suicides.  Although suicide is sometimes the tragic outcome of depression, some of those who have committed suicide while taking Cymbalta were not being treated for depression - or for any other mental illness.  Unfortunately, despite reports of suicides not linked to depression, the Food & Drug Administration (FDA) has been slow to act on Cymbalta, and has actually concealed information on some suicides that...

More Cymbalta News

Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo Protected by Copyscape Web Copyright Protection Software php-5 VendorsBay Inc